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Feline infectious peritonitis (FIP) is a high mortality infectious disease. Single nucleotide 
polymorphisms (SNPs) in the genes encoding interferon gamma (IFNG), tumour necrosis factor 
alpha (TNFA) and DC-SIGN (CD209) have been associated with increased and decreased risk 
of developing FIP. This study was designed to determine whether these associations were 
present in a UK population of pedigree cats using samples from cats euthanased with a confirmed 
diagnosis (FIP, n=22; non-FIP, n=10) or clinically healthy cats over 11 years of age (n=3).  
Methods 
DNA was extracted from tissue (n=32) or blood (n=3) and PCR performed for regions of IFNG, 
TNFA and CD209. PCR amplicons were sequenced, each SNP genotype determined, and 
genotype/allele frequency for each SNP and FIP status compared.  
Results 
No significant association was found between genotype and FIP status for any SNP analysed. 
There was a trend for the heterozygous CT genotype at both IFNG g.401 and g.408 to be 
associated with FIP (P=0.13), but this genotype was also found in a substantial proportion of non-
FIP cats. There was also a trend for the heterozygous CT genotype at IFNG g.428 to be 
associated with FIP (P=0.06), although most cats with FIP had the CC genotype at this locus. No 
associations were found between any allele at TNFA g.-421, CD209 g.1900, CD209 g.2276, 
CD209 g.2392 and CD209 g.2713 and FIP.  
Conclusions and relevance 






Feline infectious peritonitis (FIP) is a high mortality infectious disease of cats caused by feline 
coronavirus (FCoV). The prevalence of infection with FCoV can reach 90% in multi-cat 
households 1, but FIP develops in less than 5% of infected cats 2. Feline genetic factors are 
suspected of playing a role in the development of FIP with studies from North America and 
Australia showing an increased risk of FIP in pedigree over non-pedigree cats 3-6. In addition, 
some breeds 3, 4, 6, and even bloodlines within a breed 7, appear to have a higher risk of developing 
FIP than others. There also appears to be some variation in breed predisposition between 
continents 3, 4, 6. Abyssinians and Rexes were found to be at high risk and Persians at low risk in 
both the USA and Australia. However, Burmese were found to be at high risk in Australia and at 
low risk in the USA, while Himalayans (colour-point Persians) were found to be at high risk in the 
USA and at low risk in Australia. A German study found no association between breed and 
predisposition to FIP, but the number of pedigree cats included was small and mixed breed and 
Domestic shorthaired cats were amalgamated in one group 8. 
 
During the pathogenesis of FIP, following infection of enterocytes, FCoVs infects monocytes and 
macrophages where they replicate and are systemically spread 9. Entry of FCoVs into some feline 
cells is mediated by interactions between the viral spike glycoprotein and host receptor proteins, 
some of which have yet to be elucidated 10. Dendritic cell-specific intercellular adhesion molecule-
grabbing non-integrin (DC-SIGN), a mannose-binding lectin, has been shown to be a key co-
receptor during monocyte entry of both serotype I and II FCoVs 11. An aberrant immune-response 
to the presence of FCoV in macrophages and monocytes results in the development of vasculitis 
and tissue granulomas, which in turn leads to the body cavity effusions and mass lesions that 




Studies have suggested that decreased risk of developing FIP is associated with a strong Th1 
cell-mediated immunity, with higher concentrations of interferon-gamma (IFN-γ) mRNA or protein 
in the blood of healthy FCoV-infected cats compared with cats with FIP 13, 14. Interestingly, one of 
these studies also showed high levels of IFN-γ in the abdominal effusion of cats with FIP, despite 
having low levels in the blood, suggesting that cell-mediated immunity may also play a role in 
mediating pathogenesis 14. A vaccination study indicated that susceptibility to FIP also likely 
involves dysregulation of the IFN-γ/tumour necrosis factor-alpha (TNF-α) response, with 
production of high IFN-γ and low TNF-α levels associated with decreased risk, and production of 
low IFN-γ and high TNF-α levels associated with increased risk 15. Another study also showed 
that transcription of inflammatory cytokines and chemokines, including TNF-α and IFN-γ, was 
upregulated in the mesenteric lymph nodes of cats with FIP, consistent with inflammatory pathway 
activation 16. 
 
Feline single nucleotide polymorphisms (SNPs) have been associated with risk of developing FIP. 
One study that looked at the IFN-γ gene (IFNG) found the CT heterozygous genotype (CT) at 
both IFNG g.401 and IFNG g.408 to be associated with increased risk of FIP 17. These two SNPs 
appeared to be in complete linkage disequilibrium, i.e. the genotypes at these two loci were 
identical in all cats examined. In addition, the presence of a T allele at IFNG g.428 was associated 
with decreased risk of FIP. Another study that looked at the TNF-α gene (TNFA) found the 
presence of a T allele at TNFA g.-421 to be associated with decreased risk of FIP 18. In addition, 
when the DC-SIGN gene (CD209) was examined, the presence of an A allele at CD209 g.1900 
or a T allele at CD209 g.2713 were reported to be associated with increased risk of FIP, whilst 
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presence of a T allele at CD209 g.2276 or an A allele at CD209 g.2392 were found to be 
associated with decreased risk of FIP 18.  
 
The aim of the present study was to evaluate the utility of these SNPs in predicting the risk of FIP 
in a cohort of pedigree cats using samples from the Bristol FIP Biobank. 
 
Materials and Methods 
Animals and samples 
The cats in the study comprised those of known pedigree within the Bristol FIP Biobank (n=32) 
for which a definitive diagnosis of either FIP (n=22) or a disease other than FIP (n=10) were 
available, and elderly (>11 year), staff-owned pedigree cats (n=3) that were considered to be 
healthy based on history, clinical examination and blood testing. The FIP cats comprised British 
Shorthair (n=6), Ragdoll (n=6), Birman (n=3), Maine Coon (n=2), Siamese (n=2) and one each of 
Abyssinian, British Blue and Burmese. The non-FIP cats comprised Bengal (n=3), Ragdoll (n=2) 
and one each of Birman, British Shorthair, Devon Rex, Havana, Maine Coon, Persian-cross, 
Siamese and Tiffanie.  
 
For the cats from the Bristol FIP Biobank, tissue samples were collected at post-mortem 
examination. Some of these cats had been included in earlier studies 16, 19-21. Formalin-fixed tissue 
samples were subjected to histological examination, including immunohistochemistry for FCoV 
antigen to confirm FIP, and categorised as FIP or non-FIP as previously described 19. Tissue 
samples collected into RNAlater® (Life Technologies, ThermoFisher Scientific), faeces and body 
cavity fluid were stored at -80˚C prior to processing. For the staff-owned cats, excess blood from 




DNA extraction, amplification and sequencing  
Feline genomic DNA was extracted from stored samples as previously described for total nucleic 
acids 19. Feline genomic DNA was extracted from blood (100 µl) using a Chemagic 360 automated 
platform (Perkin-Elmer) in combination with the Chemagic body fluids nucleic acid kit (Perkin-
Elmer) and eluted in elution buffer (100 µl).  
 
Tissue, faeces and body cavity fluid samples from the Bristol FIP Biobank were subjected to FCoV 
quantitative reverse-transcriptase PCR, with results previously reported elsewhere 19. 
 
PCRs to amplify gene fragments containing the target SNPs were performed using 2x GoTaq 
Master Mix (Promega), 200nM forward and reverse amplification primers (see Table 1) and 5 μl 
DNA in a total volume of 25 μl. Thermal cycling was performed in a PTC-200 DNA Engine (MJ 
Research) with the following thermal profile for IFNG and TNFA: 95˚C for 2 min followed by 40 
cycles of 95˚C for 20 s, 60˚C for 20 s and 72˚C for 20 s; and the following thermal profile for 
CD209: 95˚C for 2 min followed by 35 cycles of 95˚C for 20 s, 64˚C for 20 s and 72˚C for 60 s. 
Amplicons were visualised by agarose gel (1% w/v) electrophoresis, using ethidium bromide stain 
and viewed using a GelDoc-It® Imaging System (UVP LLC, Cambridge, UK). 
 
Amplicons (IFNG 559bp (primer set 1) or 799bp (primer set 2), TNFA 498bp, CD209 1095bp) 
were purified (NucleoSpin® Extract II, Macherey-Nagel, Germany) according to the 
manufacturer’s instructions and sequenced (DNA Sequencing & Services, University of Dundee, 
Dundee, UK www.dnaseq.co.uk) (see Table 1 for primer sequences). The IFNG amplicon was 
sequenced using the forward and reverse amplification primers. The TNFA amplicon was 
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sequenced using a separate forward sequencing primer and the reverse amplification primer. The 
CD209 amplicon was sequenced using separate forward sequencing primers and the reverse 
amplification primer. The derived sequences were assembled using MacVector v15.5.4 
(MacVector Inc, Cambridge, UK). Since allele dropout was seen in some cats for IFNG using 
primer set 1, IFNG primer set 2 was used in these cats.  
 
Data Analysis 
SNPs were described relative to their genomic position from the ‘A’ of the start codon of the 
relevant gene. The association between each genotype at each position and FIP status (FIP vs. 
non-FIP; non-FIP comprised cats that were euthanased for diseases other than FIP, and the 
healthy alive cats) was analysed using Fisher’s exact test with the Freeman-Halton extension. 
The association between each allele frequency at each position and FIP status was analysed 
using Fisher’s exact test. Analyses were performed in XLSTAT v2017.6 (Addinsoft, NY, USA). A 
P value of ≤ 0.05 was considered statistically significant.  
 
Results 
Data for each sample (including FIP status and genotype for each SNP) are presented in the 
supplementary table. All cats with FIP had FCoV detectible in one or more tissue samples by 
PCR, and by definition at least one tissue was positive by immunohistochemistry for FCoV antigen 
within inflammatory lesions. Three of the deceased non-FIP cats were shedding FCoV in faeces 
at time of death and two had FCoV detected by PCR in tissue samples collected post-mortem 
(immunohistochemistry was negative for FCoV antigen in these tissues); the remaining non-FIP 
cats were negative for FCoV by PCR in all samples available for testing. FCoV serology was not 
 
 8 
available for cats in the Bristol FIP Biobank. One of the living cats was reported to be seronegative 
for FCoV at 12 years of age. 
 
IFNG SNPs 
The IFNG g.401 and g.408 SNPs were in complete linkage disequilibrium, with identical 
genotypes at these loci in all 35 cats. Table 2 shows the number and percentage of cats with 
each genotype at these loci. No genotype was found to be associated with FIP at either locus 
(P=0.13), although the percentage of cats with the heterozygous CT genotype at both loci was 
2.5 times greater in FIP cats (13/22; 59.1%) than in non-FIP cats (3/13; 23.1%). Neither the C nor 
T allele at either locus was associated with FIP status. 
 
All 13 non-FIP cats had genotype CC at IFNG g.428 whereas only 16/22 (72.7%) of FIP cats had 
this genotype. No genotype was found to be associated with FIP status at this locus (P=0.06), 
although no cats in the non-FIP group had the heterozygous CT genotype and no cats in either 
group had the TT genotype. Neither the C nor T allele at either locus was associated with FIP 
status. 
 
SNPs were also found (see the supplementary table) at IFNG g.230, IFNG g.253, IFNG g.308, 
IFNG g.333, IFNG g.468, IFNG g.523 and IFNG g.524 but none were associated with FIP status.  
 
TNFA SNPs 
No genotype at TNFA g.-421 was associated with FIP status, and neither were the C or T alleles 





All 35 cats had genotype GG at locus CD209 g.1900. At locus CD209 g.2276, 34 cats had 
genotype CC and one FIP cat had genotype CT. At locus CD209 g.2392 (Table 4), the majority 
of FIP and non-FIP cats had genotype GG, and there was no association between genotype, 
nor between G or A alleles, and FIP status. At locus CD209 g.2713 (Table 4), the majority of 
FIP and non-FIP cats had genotype CC, and there was no association between genotype, nor 
between C or T alleles, and FIP status. A further SNP was found at CD209 g.2718 (see the 
supplementary table) but was not associated with FIP status.  
 
Discussion 
A SNP describes nucleotide variation at a single point within the genome. SNPs within protein 
coding regions of a gene (i.e. exons) may change the translated amino acid sequence or result 
in premature termination of translation and protein truncation. SNPs in non-coding regions (e.g. 
introns) may increase or decrease transcription factor binding or change gene splicing and result 
in altered protein levels or alternative isoforms. Single nucleotide polymorphisms in genes such 
as IFNG, TNFA and CD209 can significantly change the amount and function of these important 
immunomodulatory proteins and potentially influence disease risk 22-25. A number of SNPs in 
these genes have been reported to be associated with increased or decreased likelihood of FIP 
17, 18. These comprise: three SNPs in non-coding regions of IFNG (intron 1 IFNG g.401, g.408, 
and IFNG g.428); one SNP within the non-coding gene promotor region of TNFA (TNFA g.-421); 
one SNP within the extracellular domain of the protein (CD209 g.1900) and three SNPs in non-
coding regions (intron 6 CD209 g.2276 and CD209 g.2392; intron 7 CD209 g.2713). Out of these 
nine SNPs only one (CD209 g.1900) is predicted to affect protein structure/function by substituting 
Trp128 for a stop codon. The previously reported intronic SNPs found associated with disease 
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status may be in linkage disequilibrium with other loci that have yet to be discovered, and it is 
these loci that confer disease susceptibility or resistance. Our study aimed to characterise these 
previously reported SNPs in a pedigree population of 35 UK cats, and compare genotype and 
SNP allele frequency to FIP status.  
 
Our results did support the previously reported finding of complete linkage disequilibrium between 
IFNG g.401 and IFNG g.408 17, as this was present in all cats tested. However, a significant 
association between the heterozygous CT genotypes at IFNG g.401 and g.408 and FIP status 
was not found in this study, although a previous study had found significance with 62.1% 
(n=18/29) of FIP cats having the CT genotypes as compared to 31.7% (n=26/82) of non-FIP cats 
(Fisher Exact; 0.004) 17. In our study there was, nonetheless, a trend for the CT genotypes to be 
more common in FIP cats (59.1%) compared with non-FIP cats (23.1%). Our study was limited 
by the number of pedigree cats that had been euthanised for a non-FIP cause, and it is possible 
that, with the greater power of a larger study, a significant association of the CT genotypes with 
FIP could have been found. However, it should be noted that in both this and the previously 
published study 17, a significant number of non-FIP cats had the CT genotypes and absence of 
the CT genotypes was not a good predictor that cats will not develop FIP. Therefore, at this time 
the selection of breeding cats based on the presence or absence of the CT genotypes at IFNG 
g.401 and IFNG g.408 cannot be recommended. 
 
There was also a trend for the heterozygous CT genotype at IFNG g.428 to be associated with 
FIP (P=0.06), although most cats with FIP and all of the non-FIP cats had the CC genotype at 
this locus. This is in contrast to previously reported findings, which showed the T allele at IFNG 
g.428 to be more prevalent in the non-FIP group 17. Indeed, in our study the T allele at IFNG g.428 
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was only found in FIP affected cats (n=6/22). The difference in association between the two 
studies might be explained by different genetic populations.  
 
Our results found no evidence of any association between FIP risk and SNPs TNFA g.-421, 
CD209 g.1900, CD209 g.2276, CD209 g.2392 and CD209 g.2713. These SNPs were previously 
reported to confer either increased (G>A at CD209 g.1900, odds ratio (OR) 3.7; C>T at CD209 
g.2713, OR 1.75) or decreased (C>T at TNFA g.-421 OR 3.9; C>T at CD209 g.2276, OR reported 
as not available; G>A at CD209 g.2392, OR 2.6) risk of developing FIP 18. In addition, these 
authors described a G>A transition at CD209 g.1900 that was not seen in our study population 
18.  
 
We are aware that the current study has several limitations; these comprise the number of cats 
included, the ‘potential’ for the non-FIP cats to have developed FIP at a later stage, and the 
possibility for genetic variation between breeds. However, all three of these limitations were also 
present in the other studies 17, 18. We had a total of 35 cats of which 13 were classified as non-
FIP and 22 as FIP. Using the genotype frequency determined for the population described in our 
study at least 28 cats would be required in each group to achieve statistical significance between 
the groups. However, we were limited by the number of pedigree cat samples that were available 
in the Bristol FIP Biobank. The possibility that the deceased cats in the non-FIP group could have 
gone on to develop FIP, were they not to have developed the alternative disease for which they 
were euthanased, cannot be ruled out. The non-FIP cats used in previous studies were all less 
than 3 years of age at time of enrolment with evidence of FCoV infection (positive by FCoV PCR 
on one or more of blood, nasal/ oral/ conjunctival/ rectal swabs, and/ or faeces) 17, 18, and were 
alive at least 2 years following recruitment in one of these studies 17, whereas in the current study, 
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the non-FIP cats had either been euthanased for reasons other than FIP with a median age of 
5.8 years (range 4 month-13.8 years), or were alive (11.8 years, as of November 2018). Data 
regarding prior exposure, infection and shedding status were available for a proportion of the non-
FIP cats (see Supplementary data 1), but not for all, so did not provide any meaningful results. 
One of the living cats with CT genotype at both IFNG g.401 and g.408 had a negative FCoV 
serology result; however, it had resided in a single cat household for nearly its entire life after 
being obtained from a multicat household as a kitten, such that early prior exposure could not be 
ruled out. FCoV serology was not available for the other two living cats. It cannot be ruled out that 
some pedigree breeds may be fixed for a single allele for a specific SNP, potentially creating bias; 
however, for the most frequently represented breeds (British Shorthair; Ragdoll; Birman) different 
genotypes were present at the target loci. It was not possible to statistically compare results within 
individual breeds due to the small numbers in each group. In the study by Hsieh and Chueh 17, 
approximately half of the cats were reported to be of known pedigree, or pedigree cross; however, 
pedigree breed and SNP status data, including any relationship between the two, were not 
reported. Future studies could focus on individual breeds for which risk of developing FIP appears 
to be greater (e.g. Abyssinians and Rexes), to exclude interbreed variation. 
 
Conclusion 
While not achieving statistical significance, the results of our study support a possible weak 
positive association between the CT genotypes at IFNG g.401/g.408 and risk of developing FIP. 
However, as the CT genotypes at these positions were present in a significant proportion of non-
FIP cats (3/13) and absent in a significant proportion of FIP cats (9/22), a genetic test based on 
these two SNPs alone to predict risk of developing FIP, or to guide breeding programmes to 
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Table 1. Primers used in PCR amplification (A) and sequencing (S) for each gene 
Gene Primer Use Sequence 
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Table 2. Interferon- gene (IFNG) genotype and allele frequency results for non-FIP and FIP 
cats included in the study. P-value indicates likelihood that a genotype or allele is associated 
with FIP status as determined by Fisher’s exact test (with the Freeman-Halton extension as 
required). 
SNP  Number of non-FIP cats (%) Number of FIP cats (%) P value 
IFNG g.401 CC 5 (38.5) 5 (22.7)  
 CT 3 (23.1) 13 (59.1) 0.13 
 TT 5 (38.5) 4 (18.2)  
 Allele C 13 (50) 23 (52.3) 1.0 
 Allele T 13 (50) 21 (47.2)  
IFNG g.408 CC 5 (38.5) 5 (22.7)  
 CT 3 (23.1) 13 (59.1) 0.13 
 TT 5 (38.5) 4 (18.2)  
 Allele C 13 (50) 23 (52.3) 1.0 
 Allele T 13 (50) 21 (47.2)  
IFNG g.428 CC 13 (100) 16 (72.7)  
 CT 0 (0.0) 6 (27.3) 0.06 
 TT 0 (0.0) 0 (0.0)  
 Allele C 26 (100) 38 (86.4) 0.08 





Table 3. Tumour necrosis factor- gene (TNFA) genotype and allele frequency results for non-
FIP and FIP cats included in the study. P-value indicates likelihood that a genotype or allele is 
associated with FIP status as determined by Fisher’s exact test (with the Freeman-Halton 
extension as required). 
SNP  Number of non-FIP cats (%) Number of FIP cats (%) P value 
TNFA g.-421 CC 12 (92.3) 20 (90.9)  
 CT 1 (7.7) 2 (9.1) 1.0 
 TT 0 (0.0) 0 (0.0)  
 Allele C 25 (96.2) 42 (95.5) 1.0 





Table 4. DC-SIGN gene (CD209) genotype and allele frequency results for non-FIP and FIP 
cats included in the study. P-value indicates likelihood that a genotype or allele is associated 
with FIP status as determined by Fisher’s exact test (with the Freeman-Halton extension as 
required). 
SNP  Number of non-FIP cats (%) Number of FIP cats (%) P value 
CD209 g.2392 GG 7 (53.8) 16 (72.7) 
 
 GA 5 (38.5) 5 (22.7) 1.0 
 AA 1 (7.7) 1 (4.6)  
 Allele G 19 (73.1) 37 (84.1) 0.36 
 Allele A 7 (26.9) 7 (15.9)  
CD209 g.2713 CC 10 (76.9) 14 (63.6) 
 
 CT 3 (23.1) 7 (31.8) 0.81 
 TT 0 (0.0) 1 (4.6)  
 Allele C 23 (88.5) 35 (79.5) 0.51 
 Allele T 3 (11.5) 9 (20.5)  
 
Legends: 
Supplementary table: Data for each sample, including FIP status, breed, age at sampling, cause 
of death (or alive at time of writing), and genotype for each SNP tested 
 
 
